Latest Oncology News

Five Under 5: Top Oncology Videos for the Week of 12/7

December 14th 2025

OncLive Staff

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

Talquetamab Plus Pomalidomide Maintains Deep, Durable Responses in R/R Multiple Myeloma

December 14th 2025

Russ Conroy

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

DREAMM-8 Study Triplet Sustains PFS, MRD-negativity in R/R Multiple Myeloma

December 14th 2025

Tim Cortese

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 12/7

December 13th 2025

OncLive Staff

The FDA approved Akeega for use in BRCA2+ mCSPC, granted priority review to the sBLA for nivolumab plus AVD in classical Hodgkin lymphoma, and more.

RAD51-Based HRD Test Could Help Refine Patient Selection for Olaparib in BRCA1/2- or PALB2-Mutant, HER2– Breast Cancer

December 13th 2025

Courtney Flaherty

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

Latest Oncology Videos

Dr Jänne on Selecting a Combination Regimen in First-Line EGFR+ NSCLC

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Dr Mayer on Efficacy Findings With Giredestrant Plus Everolimus in ER+/HER2– Advanced Breast Cancer

Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

43rd Annual Chemotherapy Foundation Symposium: The Show and After Show

Dr Gonzalez-Martin on the Safety of TUB-040 in Ovarian Cancer

Multidisciplinary Collaboration to Improve Early Recognition and Care For CA-LEMS

NCCN Guidelines and Management of CA-LEMS in the Practice

Monitoring and Optimizing Treatment Response in LEMS Management

Dr Yap on Saruparib/Camizestrant in Advanced ER+, HER2-Negative or HER2-Low Breast Cancer

Antibody-Based Strategies and the Role of R2 in Relapsed Follicular Lymphoma

Ongoing Research to Watch at ASH 2025 and Beyond

Role of BRAF Mutations in NSCLC

Endometrial Cancer: Broadening Therapeutic Options in pMMR - Insights from DUO-E/AtTEnd

Other Possible Research Avenues for Blinatumomab in ALL

Patient Profile and Treatment Selection in ALK+ NSCLC

IMvigor011: A Phase 3 Trial of Circulating Tumour (ct)DNA-Guided Adjuvant Atezolizumab vs Placebo in Muscle-Invasive Bladder Cancer

Treatment Strategies for CA-LEMS

Selecting Second-Line Therapy: Balancing Targets, Toxicities, and Durability

Endometrial Cancer: An Integrated View of LEAP-001, KEYNOTE-775, RUBY and NRG-GY018 for Treatment Strategy

Dr Punie on Patient-Reported Outcomes With Sacituzumab Govitecan vs Chemotherapy in Advanced TNBC

Dr Rugo on Elacestrant-Based Combos in ER+/HER2– Locally Advanced or Metastatic Breast Cancer

HER2 Testing Strategies, IHC Interpretation, and Tissue Stewardship in NSCLC

All Oncology News

Imlunestrant With/Without Abemaciclib Maintains PFS, OS Benefit in ER+/HER2– Breast Cancer

December 12th 2025

Jason M. Broderick

Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.

Neoadjuvant Niraparib Plus Dostarlimab Delivers 50% pCR Rate in BRCA+ or PALB2+ TNBC

December 12th 2025

Chris Ryan

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

Giredestrant-Based Combo Boosts PFS Across Subgroups in Advanced ER+/HER2– Breast Cancer After CDK4/6 Inhibition

December 12th 2025

Jonah Feldman

Giredestrant plus everolimus improved PFS across subgroups in ER-positive/HER2-negative advanced breast cancer.

Sacituzumab Govitecan Plus Pembrolizumab Yields Predictable, Manageable Safety Profile in TNBC

December 12th 2025

Sabrina Serani

Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

FDA Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC

December 12th 2025

Chris Ryan

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

Menopausal HRT Does Not Influence Breast Cancer Risk in Women Harboring BRCA Variants

December 12th 2025

Paige Britt

Menopausal hormone replacement therapy was not associated with an increased risk of breast cancer in women with BRCA mutations.

Mayo Clinic Researchers Find New Hope for Toughest Myeloma Through Off-the-Shelf Immunotherapy

December 12th 2025

Mayo Clinic

Dual-antibody, off-the-shelf therapy showed deep durable responses in patients with extra medullary multiple myeloma according to Mayo Clinic researchers.

MRD Detection With Novel ctDNA Assay Helps Determine Distant Recurrence Risk in TNBC

December 12th 2025

Tony Berberabe, MPH

MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.

TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML

December 12th 2025

Silas Inman

TERN-701 yielded a high response rate with deep molecular responses in heavily pretreated chronic phase chronic myeloid leukemia.

EMA Recommends Approval of Nogapendekin Alfa Inbakicept Plus BCG for NMIBC With CIS

December 12th 2025

Chris Ryan

The EMA recommended conditional marketing authorization for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS.

Phase 3 STAR-221 Study of First-Line Domvanalimab/Zimberelimab Plus Chemo in Upper GI Cancers to Be Discontinued

December 12th 2025

Courtney Flaherty

Both the phase 3 STAR-221 trial and phase 2 EDGE-Gastric studies of domvanalimab plus zimberelimab in upper GI cancers are being discontinued.

Gedatolisib Plus Fulvestrant ± Palbociclib Is a Potential New SOC in HR+ PIK3CA Wild-Type Advanced Breast Cancer

December 12th 2025

Kristi Rosa

Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

Experts Spotlight ASH 2025 Data Poised to Change Treatment Paradigms in AML, MZL, and Myeloma

December 12th 2025

Courtney Flaherty

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

Long-Term PALLAS Data Show No Adjusted OS Difference With Adjuvant Palbociclib in HR+/HER2– Breast Cancer

December 12th 2025

Riley Kandel

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer

December 12th 2025

Caroline Seymour

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

See All News